Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet (FERIplaq)

May 4, 2023 updated by: University Hospital, Strasbourg, France

Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms.

The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases.

The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.

Study Overview

Status

Not yet recruiting

Conditions

Allergy

Intervention / Treatment

Other: Flow cytometry

Study Type

Observational

Enrollment (Anticipated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: CHARLES AMBROISE TACQUARD, MD
Phone Number: 03 69 55 16 08
Email: charlesambroise.tacquard@chru-strasbourg.fr

Study Locations

France
- - Strasbourg, France, 67091
    - Les Hôpitaux Universitaires
    - Contact:
      
      Charles-Ambroise TACQUARD
      
      Phone Number: +33 3.69.55.16.08
      
      Email: charlesambroise.tacquard@chru-strasbourg.fr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Patients assessed in the allergy clinic of the Strasbourg University Hospital

Description

Inclusion Criteria:

Age > 18 years-old
With a protein/drug allergy (hymenoptera, arachide, amoxicillin)
Confirmed by skin tests and/or challenge test
With specific IgEs

Exclusion Criteria:

Patients who refuse to participate to this study
Patients unable to consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Presence of functionnal FcERI/RII receptors on the surface of blood platelets from allergic patients Time Frame: 1 day	After confirmation of the allergy by a well conducted allergy workup	1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Investigators

Principal Investigator: CHARLES AMBROISE TACQUARD, MD, University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2023

Primary Completion (Anticipated)

June 1, 2023

Study Completion (Anticipated)

April 1, 2025

Study Registration Dates

First Submitted

March 27, 2023

First Submitted That Met QC Criteria

May 4, 2023

First Posted (Actual)

May 8, 2023

Study Record Updates

Last Update Posted (Actual)